NMS · Biotechnology

Spero Therapeutics, Inc. (SPRO) Stock

$1.19 +4.39% NMS: SPRO Healthcare

Valuation

MetricValue
Price$1.19
Market Cap$68.90M
P/E Ratio8.50
P/B Ratio1.56
P/S Ratio1.60
EPS (TTM)$0.15
52-Week High$3.08
52-Week Low$1.08
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE16.17%
ROA13.99%
ROCE13.59%
Gross Margin0.00%
Operating Margin24.66%
Net Margin17.18%
Debt/Equity0.05
Current Ratio7.44

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$49.0M$104.0M$48.0M$60.0M
Operating Profit$-88.0M$-42.0M$21.0M$-73.0M$0
Net Profit$-90.0M$-46.0M$23.0M$-69.0M$9.0M
EPS$-2.91$-1.23$0.43$-1.27$0.15
Op Margin-2865.5%-86.9%20.7%-152.9%-0.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$171.0M$125.0M$182.0M$111.0M$69.0M
Total Liabilities$83.0M$49.0M$75.0M$64.0M$10.0M
Cash$113.0M$109.0M$76.0M$53.0M$40.0M
Borrowings$7.0M$7.0M$6.0M$4.0M$3.0M

Latest News

Sector Update: Healthcare Stocks Mixed Premarket Tuesday MT Newswires · Jul 14, 2026 Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing MT Newswires · Jul 14, 2026 Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO) InvestorsHub · Jul 14, 2026 Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties GlobeNewswire · Jul 14, 2026 Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody GlobeNewswire · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-64.0M$-8.0M$-33.0M$-23.0M$-13.0M
Investing Cash Flow$8.0M$34.0M$0$0$0
Financing Cash Flow$47.0M$0$0$0$0
Net Cash Flow$27.0M$-3.0M$-33.0M$-23.0M$-13.0M
Free Cash Flow$-64.0M$-8.0M$-33.0M$-23.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.06
EV / EBITDA2.62
FCF Yield28.42%
Quick Ratio6.12
Interest Coverage0.00
Return 1Y-33.53%
Return 3Y9.60%
Return 5Y-88.53%

Ownership

Insiders Held22.46%
Institutions Held16.16%
Institutions Float Held20.84%
Institutional HolderSharesReport Date
GSK plc9,190,6062026-03-31
Pfizer Inc2,362,3482026-03-31
Vanguard Capital Management LLC1,799,8802026-03-31
Renaissance Technologies, LLC1,189,2352026-03-31
Alphabet Inc.889,9792026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.68 -1.10% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is led by CEO Esther Rajavelu, employs 32 people, headquartered in US, publicly traded since 2017.

Spero Therapeutics, Inc. (SPRO) stock trades at $1.19 with a market capitalization of $68.90M. The stock is valued at a price-to-earnings (P/E) ratio of 8.50, price-to-book of 1.56, price-to-sales of 1.60. Over the past 52 weeks the stock has ranged between $1.08 and $3.08, and currently trades 61.4% below its 52-week high.

On profitability, Spero Therapeutics, Inc. generates a return on equity (ROE) of 16.17%, above the typical market average, return on capital employed of 13.59%, an operating margin of 24.66%, a net profit margin of 17.18%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides